Synthesis and characterization of pyrazoleanthrone derivatives as Aurora A kinase inhibitors

Abstract

Aurora A is a cell cycle kinase linked to cancer. For the purpose of finding biologically active of novel compounds and providing new ideas for drug-design, we performed virtual screening in commercially available databases and got pyrazoleanthrone with promising inhibitory activity against Aurora A. Optimization of solvent accessible C7 position of pyrazoleanthrone made us get thirteen target compounds. These pyrazoleanthrone derivatives were evaluated by Aurora A inhibition assays in vitro. The results show that some target compounds could inhibit Aurora A kinase. Meanwhile, these title compounds were tested in vitro against hepatocellular carcinoma(HepG2) cells by the 3′-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) method, showing that most of them had inhibitory potency. The inhibition rate of compound 6h was about 80% against HepG2 cells, and the IC₅₀ value was 17.4 μmol/L, which would be considered for further study.

Keywords

Pyrazoleanthrone / Aurora-A kinase / Inhibitor / Biological activity

References

[1] Glover D M, Leibowitz M H, McLean D A, Parry H. Cell, 1995, 81: 95.

[2] Andrews P D, Knatko E, Moore W J, Swedlow J R. Curr. Opin. Cell Biol., 2003, 15: 672.

[3] Andrews P D. Oncogene, 2005, 25: 5005.

[4] Qi W Q, Liu X B, Cooke L S, Persky D O, Miller T P, Squires M, Mahadevan D. Int. J. Cancer, 2012, 130: 299.

[5] Marumoto T, Zhang D, Saya H. Nat. Rev. Cancer, 2005, 5: 42.

[6] Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya P S, Lepsik M, Hajduch M. Invest. New Drugs, 2012, 30: 2411.

[7] Fujii S., Dotto G. P., Methods and Compositions for Reducing Skin Damage, WO 2007016419 A2, 2007-2-d8

[8] Howard S, Berdini V, Boulstridge J A, Carr M G, Cross D M, Curry J, Devine L A, Early T R, Fazal L, Gill A L, Heathcote M, Maman S, Matthews J E, McMenamin R L, Navarro E F, O’Brien M A, O’Reilly M, Rees D C, Reule M, Tisi D, Williams G, Vinković M, Wyatt P G. J. Med. Chem., 2009, 52: 379.

[9] Aliagas-Martin I, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang O W, Hunsaker T, Kleinheinz T, Krueger E, Liang J, Moffat J, Phillips G, Pulk R, Rawson T E, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhu B Y, Cochran A G. J. Med. Chem., 2009, 52: 3300.

[10] Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick R B, Lai Z. Protein Sci., 2008, 17: 1791.

[11] van Donggen M, Weigelt J, Uppenberg J, Schultz J, Wikstrom M. Drug Discov. Today, 2002, 7: 471.

[12] Waszkowycz B. Curr. Opin. Drug Discov. Devel., 2002, 5: 407.

[13] Chopra D, Guru R T N G. CrystEngComm, 2008, 10: 54.

[14] Kim M F, Wiemer D. Tetrahedron Lett., 2004, 45: 4977.

[15] Cheetham G M, Knegtel R M, Coll J T, Renwick S B, Swenson L, Weber P, Lippke J A, Austen D A. J. Biol. Chem., 2002, 277: 42419.

[16] Bernal C, Mendez E, Terencio J, Boronat A, Imperial S. J. Anal. Biochem., 2005, 340: 245.

[17] Liu D, Zhu X J, Jiang M, Chen H, Lan S P. Chem. J. Chinese Universities, 2012, 33(10): 2249.